Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma

Fig. 5

Chemo-immunotherapeutic effects of two nanoformulations in orthotopic CRC mouse model. a) Treatment schedule and IVIS images. b) The CT26-FL3 tumor growth over a 35-day period (n = 6, * p < 0.05 and ** p < 0.01). c) Animal survival (median survival: PBS = 40 days, Nano-FdUMP = 45 days, Nano-FdUMP with OxP and FnA = 58 days, and Nano-Folox with 5-Fu = 64 days) (n = 6, *** p < 0.001). d) Immunofluorescent staining of tumors on Day 24 (DNA fragments = green; nuclei = blue) to determine apoptosis (n = 4, * p < 0.05, relative to Nano-Folox/5-Fu). e) Level of CD8+ T cells, CD4+ T cells, memory CD8+ T cells, memory CD4+ T cells, activated DCs, MDSCs, Tregs and M2 cells in tumors on Day 24, analyzed by flow cytometry (n = 4, * p < 0.05, ** p < 0.01; NS = no significance). f) The mRNA expression of IFN-γ, TNF-α, IL-12, IL-4, IL-6 and IL-10 in tumors on Day 24 (n = 4, * p < 0.05). g) Orthotopic CT26-FL3 tumor growth treated with Nano-FdUMP/Nano-Folox after the removal of CD4+ or CD8+ T cells (n = 4, * p < 0.05 and ** p < 0.01)

Back to article page

Molecular Cancer

ISSN: 1476-4598